# Neuralink — Healthcare Investment Intelligence

> other · Series B. MedFuel Intel profile as of 2026-06-12.

Neuralink is a neurotechnology company developing implantable brain-computer interfaces (BCIs) for treating brain diseases and human enhancement. As of 2024, it has conducted human implants, received FDA approval in May 2023, and progressed through multiple funding rounds including Series B and later stages.

## Key facts (as of 2026-06-12)
- Sector: other
- Stage: Series B
- Website: https://neuralink.com

## MedFuel assessment
- Intelligence score: 0/100
- Analyses: 0
- Sentiment trend: stable

---
Source: MedFuel Intel — https://medfuelintel.com/company/neuralink-7. Figures reflect MedFuel's analysis; verify against primary sources (SEC, FDA, ClinicalTrials.gov) before any investment decision.